AJP - Regu Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol (February 20, 2008). doi:10.1152/ajpregu.00864.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/4/R1220    most recent
00864.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sullivan, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sullivan, J. C.
Submitted on December 3, 2007
Accepted on February 18, 2008

Sex and the Renin-Angiotensin System: Inequality Between the Sexes in Response to RAS Stimulation and Inhibition

Jennifer C. Sullivan1*

1 Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, United States

* To whom correspondence should be addressed. E-mail: jsullivan{at}mail.mcg.edu.

The purpose of this review is to examine sex differences in response to stimulation and inhibition of the renin-angiotensin system (RAS). The RAS plays a prominent role in the development of chronic renal disease and there are known sex differences in not only the expression level of components of the RAS, but also in how males and females respond to perturbations of the RAS. In men, renal injury increases in parallel with increased activation of the RAS, while in women increases in Ang II do not necessarily translate into increases in renal injury. Moreover, both epidemiological and experimental studies have noted sex differences in the therapeutic benefits following angiotensin converting enzyme inhibitor and angiotensin receptor blocker treatment. Despite these differences, RAS inhibitors are the most commonly prescribed drugs for the treatment of chronic renal disease irrespective of sex. This review will examine how males and females respond to stimulation and inhibition of the RAS, with a focus on renal disease.




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
M. White, H. Ross, S. Levesque, L. Whittom, G. B Pelletier, N. Racine, S. Meloche, and L. Voisin
Effects of Angiotensin-Converting Enzyme Inhibitor Versus Valsartan on Cellular Signaling Events in Heart Transplant
Ann. Pharmacother., May 1, 2009; 43(5): 831 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. S. Gilbert and M. J. Nijland
Sex differences in the developmental origins of hypertension and cardiorenal disease
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2008; 295(6): R1941 - R1952.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.